Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
- Conditions
- Systemic Lupus ErythematosusActive Cutaneous Lupus Erythematosus
- Interventions
- Drug: BIIB059 (litifilimab)Drug: Placebo
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Biogen
- Target Recruit Count
- 264
- Registration Number
- NCT02847598
- Locations
- 🇺🇸
TriWest Research Associates, LLC, El Cajon, California, United States
🇺🇸Purushotham Akther & Rosan Kotha, MD Inc., La Mesa, California, United States
🇺🇸Pinnacle Research Group LLC, Anniston, Alabama, United States
Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes
- Conditions
- Acute Optic NeuritisMultiple Sclerosis
- Interventions
- Drug: BIIB033 (opicinumab)
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 28
- Registration Number
- NCT02833142
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 64
- Registration Number
- NCT02831517
- Locations
- 🇬🇧
Research Site, Leeds, United Kingdom
A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 36
- Registration Number
- NCT02829541
- Locations
- 🇺🇸
Research Site, Evansville, Indiana, United States
Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 28
- Registration Number
- NCT02782975
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 2978
- Registration Number
- NCT02776072
- Locations
- 🇬🇧
Research Site, Chertsey, Surrey, United Kingdom
Absorption, Metabolism, and Excretion Study of BIIB074
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 6
- Registration Number
- NCT02751905
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 277
- Registration Number
- NCT02730455
- Locations
- 🇬🇧
Research Site, Stoke on Trent, Staffordshire, United Kingdom
Effect of Itraconazole on the Pharmacokinetics of BIIB074
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 16
- Registration Number
- NCT02698267
- Locations
- 🇬🇧
Research Site, Leeds, United Kingdom
Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers
- Conditions
- Healthy Adult SubjectsHealthy Elderly Subjects
- Interventions
- First Posted Date
- 2016-02-25
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Biogen
- Target Recruit Count
- 97
- Registration Number
- NCT02691702
- Locations
- 🇺🇸
QPS-MRA, LLC (Miami Research Associates), South Miami, Florida, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States